Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for the AIMday in Women's Health.

Banner with AIMday logo and view of delegates at an AIMday

The University of Oxford is hosting an AIMday in Women’s Health industry event on Wednesday 23 June 2021. This event will bring together industry with academia to discuss key challenges in women’s health.  

The AIMday format allows industry to propose challenges for one-hour roundtable discussions with groups of relevant academics and clinicians from Oxford. For academics, this is a great chance to see how your research can be applied in industry and to meet potential future collaborators. View the list of challenges put forward by industry.

Participating companies include: Ferring Pharmaceuticals, Fertility Circle, Natural Cycles, Gynica, MirZyme Therapeutics, Syrona Health, Altus Life Sciences, Cambridge Digital Health, OCON Healthcare & Endodiag.

Academic registration is now open and will close on Friday 4 June. Advance registration is essential.

Read more about the AIMday in Women's Health and register to attend.

For more details, please contact Amira Burshan, Business Engagement Facilitator, Business Partnerships Office.

We are planning to hold this AIMday as an in-person event, Covid restrictions permitting. If this is not possible, the event will be postponed until we can do a face-to-face meeting (likely postponing initially to Autumn 2021). We will keep you updated in advance of our plans.

Similar stories

Innovation award for Professor Anindita Roy to develop new treatments for childhood cancer

Awards and Appointments General Innovation Research

Associate Professor Andi Roy leads one of the five research teams across the UK that have been awarded the 2021 Cancer Research UK-Children with Cancer UK Innovation Award. The awards, which provide a total of £4.3 million in scientific funding, will allow leading researchers in the field to delve into the biology of children’s and young people’s cancers, with the hope of finding new ways to prevent and treat these complex cancers.

Association of Physicians of Great Britain and Ireland Annual Meeting opens to wider medical community for first time in over a century

Events General

Established in 1907, the Association of Physicians of Great Britain and Ireland (AoPGBI) has traditionally only invited the highest-profile doctors and researchers to its annual meeting. Now, they have made the landmark decision to open their (virtual) doors to the wider medical community, primarily to clinicians, early career researchers, discovery scientists and industry affiliates.

Oxford vaccine creator Professor Sarah Gilbert awarded RSA Albert Medal

Awards and Appointments Coronavirus COVID-19 General Innovation Research

Professor Sarah Gilbert has been awarded the Royal Society for Arts, Manufactures and Commerce’ (RSA) Albert Medal for her work on the Oxford vaccine.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Oxford to collaborate with Janssen to map the cellular landscape of immune mediated disorders

General Innovation

The University of Oxford announced today that it has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

BioEscalator’s Enara Bio partners with Boehringer Ingelheim to develop novel cancer immunotherapies

General Innovation

Enara Bio, a start-up located in the University’s BioEsclator, has announced a strategic collaboration and licensing agreement with Boehringer Ingelheim, worth over €876M (£787M), to lead the discovery and validation of Dark Antigens to target lung and gastrointestinal cancers.